Skip to main content
Premium Trial:

Request an Annual Quote

Telesis Bio: William Kullback

Synthetic biology company Telesis Bio has appointed William Kullback as CFO. Kullback previously was CFO of BioLegend where he helped lead that company's $5.25 billion September 2021 sale to Revvity (PerkinElmer at the time). Before BioLegend, Kullback was CFO of Lombard Medical from 2014 to 2017, prior to its acquisition by MicroPort Scientific. He holds an MBA and bachelor's degree from the State University of New York at Buffalo.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.